A complete application in a minute
Tailored resume and cover letter, ready to send.
Zealand Pharma A/S is seeking an Associate QA Manager in Quality Systems to take day-to-day ownership of core QA processes during a 12-month maternity cover. The role focuses on keeping processes running, enabling improvements, and representing QA in audits and inspections.
You will work cross-functionally, train colleagues globally, and help implement the Zealand Pharma QMS landscape while maintaining regulatory readiness across GxP areas.
Does it excite you to work with core QA processes that keep a QMS running in practice, and do you have experience with Change Control, Deviation and CAPA? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague. Your new position As Associate QA Manager in Quality Systems, you will take over day-to-day ownership of core QA processes during a 12-month maternity cover. You will keep the processes running, improve them where it makes a difference, and represent them in audits and inspections. You will work closely with colleagues across the company, and the position reports to the Head of Quality Systems.
We offer exciting responsibilities:
You are structured and pragmatic, and you turn requirements into solutions that are easy to follow in practice. You work independently while being a motivated team player who drives results with a quality-first mindset. MSc or equivalent in a relevant field QA experience, preferably within pharmaceutical quality systems Experience presenting and defending quality processes to stakeholders, auditors or inspectors Ability to translate regulatory and GxP requirements into practical process solutions Familiarity with Veeva Vault (our EDMS/QMS) is a plus
You will join the Quality Systems team, a group of 9 specialists focused on maintaining and improving the Zealand Pharma QMS across all GxP areas. We are part of the QA organization, and we hold process ownership of key QA functions, including Change Control, Deviation, CAPA, Document & Records Management, Training and Inspection Handling.
Let’s bond and be bold We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.
For further information, please contact Head of Quality Systems, Kamilla Vagtborg: KVagtborg@zealandpharma.com.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com. #LI-Onsite Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.